Attached files
file | filename |
---|---|
EX-31.4 - EX-31.4 - Myovant Sciences Ltd. | d602799dex314.htm |
EX-31.3 - EX-31.3 - Myovant Sciences Ltd. | d602799dex313.htm |
EX-10.5 - EX-10.5 - Myovant Sciences Ltd. | d602799dex105.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2018
or
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 001-37929
Myovant Sciences Ltd.
(Exact name of registrant as specified in its charter)
Bermuda | 98-1343578 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
Suite 1, 3rd Floor 11-12 St. Jamess Square London SW1Y 4LB United Kingdom |
Not Applicable | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: +44 203 318 9709
(former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act. (Check one)
Large accelerated filer | ☐ | Accelerated filer | ☒ | |||
Non-accelerated filer | ☐ (Do not check if a smaller reporting company) | Smaller reporting company | ☐ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares outstanding of the Registrants common shares, $0.000017727 par value per share, on August 3, 2018, was 68,225,552.
EXPLANATORY NOTE
Myovant Sciences Ltd. (Myovant) is filing this Amendment No. 1 to Quarterly Report on Form 10-Q/A (this Amendment) to amend Myovants Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018, as filed with the Securities and Exchange Commission (the SEC) on August 7, 2018 (the Form 10-Q). This Amendment is an exhibit-only filing. This Amendment is being filed solely to re-file a revised redacted version of Exhibit 10.5 to the Form 10-Q to reflect changes to Myovants confidential treatment request with respect to certain portions of Exhibit 10.5. Except for the changes to Exhibit 10.5, this Amendment does not otherwise update any exhibits as originally filed or previously amended.
No attempt has been made in this Amendment to modify or update the other disclosures presented in the Form 10-Q. This Amendment does not reflect events occurring after the filing of the Form 10-Q or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Form 10-Q and Myovants other filings with the SEC.
In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by Myovants principal executive officer and principal financial officer are filed as exhibits to this Amendment (Exhibits 31.3 and 31.4). Myovant is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.
1
Item 6. Exhibits.
| Filed herewith. |
+ | Previously filed with the Companys Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018, as filed on August 7, 2018. |
2
* | Confidential treatment has been requested for portions omitted from this exhibit (indicated by asterisks) and those portions have been separately filed with the SEC. |
** | These certifications were previously furnished solely to accompany the Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and are not filed for purposes of Section 18 of the Exchange Act, as amended, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MYOVANT SCIENCES LTD. | ||||||
Date: September 17, 2018 |
By: |
/s/ Frank Karbe | ||||
Frank Karbe (Duly Authorized Officer and Principal Financial and Accounting Officer) |